1. Clinical research has shown potential therapeutic activity of mushrooms in the following psychiatric conditions EXCEPT:
A. Depression
B. OCD
C. Anxiety resulting from terminal illness
D. Schizophrenia
2. What is psilocybin's active metabolite?
A. LSD
B. Psilocin
C. DMT
D. An inactive entity
3. What is mechanism of action of psychedelics (including mushroom products)?
A. Agonist at serotonin 5HT2A receptors
B. Antagonist at 5HT1A receptors
C. Inhibition of serotonin reuptake
D. Agonist at dopamine receptors
4. What is the usual dose of psilocybin found to be efficacious in clinical research studies?
A. 3 micrograms/kg
B. 30 micrograms/kg
C. 300 micrograms/kg
D. 3 mg/kg
5. Many of the clinical studies of psilocybin report positive effects persisting for:
A. More than a day
B. More than a week
C. More than a month
D. Up to 6 months
6. Which of the following is one of psilocybin's common side effects?
A. Nausea
B. Hypertension
C. Bradycardia
D. Panic attacks
7. More research has been conducted using LSD than psilocybin, but what is psilocybin's potential clinical advantage over LSD?
A. It is more potent than LSD
B. It has lower addiction potential than LSD
C. It has milder systemic effects than LSD
D. There are no advantages
8. Why did clinical research with psychedelics decline in the 1970s?
A. Clinical trial results were not very encouraging
B. Newly developed antidepressants made it unnecessary
C. The Controlled Substances Act made research difficult
D. Psychedelic drugs were in short supply
9. Which of the following cities has decriminalized possession of magic mushrooms?
A. Santa Barbara, CA
B. Burlington, VT
C. Denver, CO
D. Detroit, MI
10. What state was first to approve the use of psilocybin in a medical/therapy setting?
A. California
B. Oregon
C. Colorado
D. Kansas
11. What has the FDA done with respect to psilocybin?
A. Awarded it breakthrough status for treatment resistant depression
B. Approved limited use in combination with selective serotonin reuptake inhibitors
C. Refused to approve clinical trials the employ it in any of its forms
D. Required further data on dosing and long-term adverse effects
12. Patients may experience greater psilocybin effects if they do one of the following EXCEPT:
A. Take an MAO inhibitor
B. Co-consume alcohol
C. Are heavy smokers
D. Take anti-psychotic drugs
Evaluation Questions
13. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
24. Will the information presented cause you to change your practice?
A. Yes
B. No
25. Are you committed to making these changes?
A. Yes
B. No
26. As a result of this activity, did you learn something new?
A. Yes
B. No
27. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
28. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20